Neutrophil Gelatinase-associated Lipocalin Concentration in Coronary Artery Disease
|Coronary Artery Disease Atherosclerosis|
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Neutrophil Gelatinase-associated Disease: a Potential Biomarker of the Severity of Coronary Artery Disease|
|Study Start Date:||September 2008|
|Study Completion Date:||September 2009|
|Primary Completion Date:||March 2009 (Final data collection date for primary outcome measure)|
Patients with angiographically confirmed significant CAD
Patients without significant CAD
Inflammation is considered to play a major role in coronary artery disease (CAD) which accounts for high morbidity and mortality rates in the western world. Several lines of evidence support a role for neutrophils in the development of atherosclerosis and its progression.
Neutrophil gelatinase-associated lipocalin (NGAL), also known as Lipocalin-2, is a 25-kDa secretory glycoprotein that was originally identified in mouse kidney cells and human neutrophil granules. This protein has been used as a marker of neutrophil activation in several studies, while recently it was found to be an inflammatory marker closely related to obesity and its metabolic complications.
Recently, lactoferrin, a protein which co-localizes with NGAL in the specific granules of human neutrophils has been proposed as a more dynamic marker of neutrophil activation compared to the widely used myeloperoxidase in patients with CAD.
In line with the accumulating evidence, this study is designed to investigate the relationship between serum NGAL concentration and the presence or the severity of coronary artery disease according to coronary angiography.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00749281
|Athens, Attica, Greece, 11521|
|Study Chair:||Demosthenes Katritsis, MD,PhD||Athens Euroclinic and Cardiovascular Research Society|